neurology
Multiple sclerosis

First medication for SPMS listed on PBS

Siponimod (Mayzent) will be listed on the PBS from 1 November for the treatment of patients with secondary progressive multiple sclerosis. The oral treatment, which would otherwise cost $25,000 per year, is in the same class as fingolimod, and is the only one approved specifically to treat SPMS in Australia The listing follows a review ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic